FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Artal International S.C.A.
2. Issuer Name and Ticker or Trading Symbol

LEXICON PHARMACEUTICALS, INC. [ LXRX ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

VALLEY PARK, 44, RUE DE LA VALLEE
3. Date of Earliest Transaction (MM/DD/YYYY)

12/16/2020
(Street)

LUXEMBOURG, N4 L-2661
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/16/2020  P(1)  10937500 A$3.20 32259461 I See Footnotes (2)(5)(6)(7)
Common Stock         3516214 I See Footnotes (3)(5)(6)(7)
Common Stock         35402689 I See Footnotes (4)(5)(6)(7)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:
(1) On December 11, 2020, Artal International S.C.A. entered into a subscription agreement with the Issuer and other parties thereto, pursuant to which Artal International S.C.A. agreed to purchase 10,937,500 shares of Class A common stock of the Issuer at a price of $3.20 per share. The purchase closed on December 16, 2020.
(2) These securities are directly held by Artal International S.C.A.
(3) These securities are directly held by Invus Public Equities, L.P.
(4) These securities are directly held by Invus, L.P.
(5) Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal Treasury Limited is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. and, through its Geneva branch, is the sole stockholder of Artal Treasury Limited. The managing partner of Artal International S.C.A. is Artal International Management S.A. The parent company of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.
(6) Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
(7) Due to the limitations of the electronic filing system certain Reporting Persons are filing a separate Form 4.

Remarks:
Invus C.V. directly holds 4,321,214 shares of Issuer common stock. None of the Reporting Persons listed in Footnote 5 hereof have any beneficial or pecuniary interest for purposes of Section 16 of the Exchange Act in the shares of Issuer common stock directly held by Invus C.V. For purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Artal International S.C.A.
VALLEY PARK, 44, RUE DE LA VALLEE
LUXEMBOURG, N4 L-2661
XX

Minne Pascal
8 CLOS DU BOCAGE
GENVAL, C9 B-1332
XX

Artal International Management S.A.
VALLEY PARK, 44, RUE DE LA VALLEE
LUXEMBOURG, N4 L-2661
XX

Artal Group S.A.
VALLEY PARK, 44, RUE DE LA VALLEE
LUXEMBOURG, N4 L-2661
XX

Westend S.A.
VALLEY PARK, 44, RUE DE LA VALLEE
LUXEMBOURG, N4 L-2661
XX

Stichting Administratiekantoor Westend
CLAUDE DEBUSSYLAAN 46
AMSTERDAM, P7 1082 MD
XX


Signatures
See Signatures Included in Exhibit 99.112/16/2020
**Signature of Reporting PersonDate

Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Lexicon Pharmaceuticals Charts.
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Lexicon Pharmaceuticals Charts.